HCPCS Level IIdrugActive
J2779
Inj, susvimo 0.1 mg
BETOS: O1E
Effective: 2022-07-01
Referenced in 3 policies
Description
Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Susvimo
Manufacturer
Genentech, Inc.
HCPCS Dosage
0.1 MG
Billing Units
100.0000
2
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.